Cargando…

Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue

INTRODUCTION: Tau pathology is a major age-related event in Down syndrome with Alzheimer’s disease (DS-AD). Although recently, several different Tau PET tracers have been developed as biomarkers for AD, these tracers showed different binding properties in Alzheimer disease and other non-AD tauopathi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lemoine, L., Ledreux, A., Mufson, E. J., Perez, S. E., Simic, G., Doran, E., Lott, I., Carroll, S., Bharani, K., Thomas, S., Gilmore, A., Hamlett, E. D., Nordberg, A., Granholm, A. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682014/ https://www.ncbi.nlm.nih.gov/pubmed/33222700 http://dx.doi.org/10.1186/s13024-020-00414-3

Ejemplares similares

Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer’s disease cases
por: Malarte, Mona-Lisa, et al.
Publicado: (2020)

Small Neuron-Derived Extracellular Vesicles from Individuals with Down Syndrome Propagate Tau Pathology in the Wildtype Mouse Brain
por: Ledreux, Aurélie, et al.
Publicado: (2021)

In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer’s Brain Tissue
por: Ni, Ruiqing, et al.
Publicado: (2021)

Editorial: Down Syndrome, Neurodegeneration and Dementia
por: Mufson, Elliott J., et al.
Publicado: (2021)

A noradrenergic lesion aggravates the effects of systemic inflammation on the hippocampus of aged rats
por: Bharani, Krishna L., et al.
Publicado: (2017)

Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging
por: Murugan, N. Arul, et al.
Publicado: (2019)

Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau Fibrils
por: Zhou, Yang, et al.
Publicado: (2021)

Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brains
por: Malarte, Mona-Lisa, et al.
Publicado: (2022)

Amyloid‐β PET and CSF in an autopsy‐confirmed cohort
por: Reimand, Juhan, et al.
Publicado: (2020)

Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains
por: Lemoine, Laetitia, et al.
Publicado: (2017)

Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer’s Tauopathy
por: Murugan, N. Arul, et al.
Publicado: (2021)

Brain amyloid and the transition to dementia in Down syndrome
por: Keator, David B., et al.
Publicado: (2020)

Insight into the Binding of First- and Second-Generation PET Tracers to 4R and 3R/4R Tau Protofibrils
por: Li, Junhao, et al.
Publicado: (2023)

Down syndrome: Distribution of brain amyloid in mild cognitive impairment
por: Keator, David B., et al.
Publicado: (2020)

Structural tract alterations predict down-stream tau accumulation in amyloid positive older individuals
por: Jacobs, Heidi I.L., et al.
Publicado: (2018)

The development and validation of tau PET tracers: current status and future directions
por: Okamura, Nobuyuki, et al.
Publicado: (2018)

Discriminatory ability of next-generation tau PET tracers for Alzheimer’s disease
por: Yap, Steven Y, et al.
Publicado: (2021)

Tau PET imaging: present and future directions
por: Saint-Aubert, Laure, et al.
Publicado: (2017)

Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study
por: Padilla, Concepcion, et al.
Publicado: (2022)

AMYQ: An index to standardize quantitative amyloid load across PET tracers
por: Pegueroles, Jordi, et al.
Publicado: (2021)

Amyloid- β and tau deposition influences cognitive and functional decline in Down syndrome
por: Grigorova, Monika, et al.
Publicado: (2022)

A New Role for RNA G-quadruplexes in Aging and Alzheimer’s Disease
por: Kallweit, Lena, et al.
Publicado: (2023)

Amyloid duration is associated with preclinical cognitive decline and tau PET
por: Koscik, Rebecca L., et al.
Publicado: (2020)

The Sensitivity of Tau Tracers for the Discrimination of Alzheimer’s Disease Patients and Healthy Controls by PET
por: Mohammadi, Zohreh, et al.
Publicado: (2023)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Amyloid-Targeting PET Tracer [(18)F]Flutemetamol Accumulates in Atherosclerotic Plaques
por: Hellberg, Sanna, et al.
Publicado: (2019)

Mapping the association between tau-PET and Aβ-amyloid-PET using deep learning
por: Ruwanpathirana, Gihan P., et al.
Publicado: (2022)

Research attitudes in families of individuals with Down syndrome: importance for clinical trials
por: Lott, Ira T., et al.
Publicado: (2022)

Tau PET imaging in neurodegenerative tauopathies—still a challenge
por: Leuzy, Antoine, et al.
Publicado: (2019)

Astroglial tracer BU99008 detects multiple binding sites in Alzheimer’s disease brain
por: Kumar, Amit, et al.
Publicado: (2021)

Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease
por: Jie, Caitlin V. M. L., et al.
Publicado: (2021)

Focal amyloid and asymmetric tau in an imaging-to-autopsy case of clinical primary progressive aphasia with Alzheimer disease neuropathology
por: Martersteck, Adam, et al.
Publicado: (2022)

Dysfunction of the retromer complex system contributes to amyloid and tau pathology in a stem cell model of Down syndrome
por: Curtis, Mary Elizabeth, et al.
Publicado: (2022)

Blood Beta-Amyloid and Tau in Down Syndrome: A Comparison with Alzheimer’s Disease
por: Lee, Ni-Chung, et al.
Publicado: (2017)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
por: Startin, Carla M., et al.
Publicado: (2019)

Tau Filaments and the Development of Positron Emission Tomography Tracers
por: Goedert, Michel, et al.
Publicado: (2018)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

NPT088 reduces both amyloid-β and tau pathologies in transgenic mice
por: Levenson, Jonathan M., et al.
Publicado: (2016)

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Bischof, Gérard N, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ihccmopmtraccil7gg3ptu5auk